evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

14 questions · 28 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 15 · 53.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 10 · 35.7%Moderate 2 · 7.1%High 1 · 3.6%

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

Usual care with ivabradine showed no clear difference in mortality from cardiovascular causes ( compared with placebo, usual care, or no treatment (moderate certainty).

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Costs · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Cardiovascular mortality · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Time to first hospitalisation for heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Number of days spent in hospital due to heart failure during · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Rate of serious adverse events · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Quality of life · adults (≥ 18 years of age) with a diagnosis of chronic heart failure with reduced ejection fraction (HFrEF)
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Exercise capacity · patients with chronic heart failure with preserved ejection fraction
2 findings from 1 review

Usual care with ivabradine vs Placebo, no intervention or usual care (with or without placebo)

Costs · patients with chronic heart failure with preserved ejection fraction

The review found no eligible studies for this question.

2 findings from 1 review